WALTHAM, Mass --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media

Record number of SENSUS™ devices sold Launch of second generation SENSUS device Strong growth in domestic DPNCheck ® tests Progress toward DPNCheck launch in Japan WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disturbances, today said it plans

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep

Close collaboration with Omron Healthcare in preparation of the Filing WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC-stat

Discussion of Diagnosis and Treatment of Diabetic Peripheral Neuropathy WALTHAM, Mass. --(BUSINESS WIRE)-- Shai N. Gozani , M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto .

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the